Hypoxanthine Derivatives in Experimental Infections
In vivo treatment with parenterally administered hypoxanthine derivatives, notably ST 789, was able to protect cyclophosphamide-immunosuppressed mice against experimental infections with both bacterial and fungal pathogens. However, the mechanisms accounting for these effects of hypoxanthine derivat...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/181709 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550297882329088 |
|---|---|
| author | Claudio De Simone Edoardo Arrigoni Martelli Pietro Foresta Giuseppe Famularo Roberto Giacomelli Emilio Jirillo Vito Ruggiero Giorgio Tonietti |
| author_facet | Claudio De Simone Edoardo Arrigoni Martelli Pietro Foresta Giuseppe Famularo Roberto Giacomelli Emilio Jirillo Vito Ruggiero Giorgio Tonietti |
| author_sort | Claudio De Simone |
| collection | DOAJ |
| description | In vivo treatment with parenterally administered hypoxanthine
derivatives, notably ST 789, was able to protect cyclophosphamide-immunosuppressed mice against
experimental infections with both bacterial and fungal pathogens. However, the mechanisms accounting
for these effects of hypoxanthine derivatives remain to be fully established. In fact, only the treatment with
ST 789 resulted in a clear enhancement of the primary antibody production as well as macrophage
phagocytic activity, whereas T lymphocyte responsiveness to mitogens and both macrophage- and natural
killer-dependent cytotoxicity were not significantly affected. These data, together with the recently shown
ability of ST 789 to increase interleukin-6 production, suggest that monocyte/macrophages are likely to be the main cellular target of the immunomodulating activity of ST 789. Finally, in the presentln vivo study, hypoxanthine derivatives did not enhance the mean survival time of tumour-bearing immunosuppressed mice. |
| format | Article |
| id | doaj-art-a1c7ef13508d42d4bbc9809fbd10f950 |
| institution | Kabale University |
| issn | 1180-2332 |
| language | English |
| publishDate | 1992-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases |
| spelling | doaj-art-a1c7ef13508d42d4bbc9809fbd10f9502025-02-03T06:07:09ZengWileyCanadian Journal of Infectious Diseases1180-23321992-01-013Suppl B10611010.1155/1992/181709Hypoxanthine Derivatives in Experimental InfectionsClaudio De Simone0Edoardo Arrigoni Martelli1Pietro Foresta2Giuseppe Famularo3Roberto Giacomelli4Emilio Jirillo5Vito Ruggiero6Giorgio Tonietti7Infectious Diseases and Internal Medicine, L'Aquila, ItalySigma Tau, Pomezia, ItalySigma Tau, Pomezia, ItalyInfectious Diseases and Internal Medicine, L'Aquila, ItalyInfectious Diseases and Internal Medicine, L'Aquila, ItalyInfectious Diseases and Internal Medicine, L'Aquila, ItalySigma Tau, Pomezia, ItalyInfectious Diseases and Internal Medicine, L'Aquila, ItalyIn vivo treatment with parenterally administered hypoxanthine derivatives, notably ST 789, was able to protect cyclophosphamide-immunosuppressed mice against experimental infections with both bacterial and fungal pathogens. However, the mechanisms accounting for these effects of hypoxanthine derivatives remain to be fully established. In fact, only the treatment with ST 789 resulted in a clear enhancement of the primary antibody production as well as macrophage phagocytic activity, whereas T lymphocyte responsiveness to mitogens and both macrophage- and natural killer-dependent cytotoxicity were not significantly affected. These data, together with the recently shown ability of ST 789 to increase interleukin-6 production, suggest that monocyte/macrophages are likely to be the main cellular target of the immunomodulating activity of ST 789. Finally, in the presentln vivo study, hypoxanthine derivatives did not enhance the mean survival time of tumour-bearing immunosuppressed mice.http://dx.doi.org/10.1155/1992/181709 |
| spellingShingle | Claudio De Simone Edoardo Arrigoni Martelli Pietro Foresta Giuseppe Famularo Roberto Giacomelli Emilio Jirillo Vito Ruggiero Giorgio Tonietti Hypoxanthine Derivatives in Experimental Infections Canadian Journal of Infectious Diseases |
| title | Hypoxanthine Derivatives in Experimental Infections |
| title_full | Hypoxanthine Derivatives in Experimental Infections |
| title_fullStr | Hypoxanthine Derivatives in Experimental Infections |
| title_full_unstemmed | Hypoxanthine Derivatives in Experimental Infections |
| title_short | Hypoxanthine Derivatives in Experimental Infections |
| title_sort | hypoxanthine derivatives in experimental infections |
| url | http://dx.doi.org/10.1155/1992/181709 |
| work_keys_str_mv | AT claudiodesimone hypoxanthinederivativesinexperimentalinfections AT edoardoarrigonimartelli hypoxanthinederivativesinexperimentalinfections AT pietroforesta hypoxanthinederivativesinexperimentalinfections AT giuseppefamularo hypoxanthinederivativesinexperimentalinfections AT robertogiacomelli hypoxanthinederivativesinexperimentalinfections AT emiliojirillo hypoxanthinederivativesinexperimentalinfections AT vitoruggiero hypoxanthinederivativesinexperimentalinfections AT giorgiotonietti hypoxanthinederivativesinexperimentalinfections |